ß-thalassemia Clinical Trial
Official title:
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
Regular blood transfusions are essential for the management of haematological conditions such as β-thalassemia major. As a result, however, patients with these conditions are susceptible to the development of transfusion-dependent iron overload (hemosiderosis or secondary iron overload
In the absence of a naturally occurring physiological mechanism for the removal of excess
iron in the body, life-long treatment and adherence to iron chelation therapy (ICT) are
necessary to prevent the morbidity and mortality that may result if excess iron is allowed to
.
Deferasirox (DFO),is the oldest available form of ICT used by patients with
transfusion-dependent disorders. Improvements in ICT administration convenience and
tolerability are expected to improve patient's satisfaction with ICT and Health Related
Quality of Life (HRQOL), thus promoting adherence to ICT regimens and potentially reducing
iron overload-related morbidity/mortality and associated healthcare costs
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00560820 -
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
|
Phase 1 | |
| Recruiting |
NCT05864170 -
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
|
Early Phase 1 | |
| Completed |
NCT04054921 -
Safety Study for Beta Thalassemia Subjects on PTG-300
|
Phase 2 | |
| Not yet recruiting |
NCT05773729 -
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
|
N/A | |
| Not yet recruiting |
NCT05776173 -
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
|
N/A | |
| Completed |
NCT03802201 -
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
|
Phase 2 | |
| Recruiting |
NCT05745532 -
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
|
Early Phase 1 | |
| Recruiting |
NCT05494333 -
Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia
|